非霍奇金氏淋巴瘤骨髓微小病灶检测的临床意义  

The clinical significance of detecting minimal residual disease in non Hodgkin's lymphoma

作　　者：肖若芝[1] 周宇麒[1] 

机构地区：[1]中山医科大学附属第三医院内科,广州510630

出　　处：《癌症》1999年第6期705-707,共3页Chinese Journal of Cancer

摘　　要：目的 :探讨微小病灶在非霍奇金氏淋巴瘤中的检测对病人疗效、预后的影响。方法 :采用PCR方法扩增T细胞受体γ链 (TCRγ)和免疫球蛋白重链 (IgH)基因重排 ,对 13例骨髓形态学检查正常的T细胞非霍奇金氏淋巴瘤 (T NHL)和 17例B细胞非霍奇金氏淋巴瘤 (B NHL)病人治疗前骨髓标本进行微小病灶 (MRD)检测。结果 :其中 7例T NHL病人发生TCRγ基因重排 ,检出率为 5 3 8% ,11例B NHL病人发生IgH基因重排 ,检出率为 6 4 8%。检出阳性的病人生存期明显低于检出阴性的病人 (P <0 0 5 )。结论 :骨髓中微小病灶检测可以协助估计病人预后。Objective:To analyze the significance of detecting minimal residual disease (MRD) in non Hodgkins lymphoma Methods:polymerase chain reaction (PCR) was used to amplify the T cell receptor γchain gene (TCRγ) in T cell non Hodgkins lymphoma (T NHL) and immunoglobulin gene rearrangements (IgH) in B cell non Hodgkins lymphoma(B NHL) Bone marrow specimens from 13 untreated patients of T NHL with normal morphology and 17 patients of B NHL were detected for MRD Results:TCR γrearrangement was shown in 7 patients with T NHL and IgH rearrangement was shown in 11 patients with B NHL The incidence of MRD in bone marrow with T NHL and B NHL was 53 8%(7/13) and 64 8%(11/17) respectively Patients with MRD had a shorter survival time than those without (P< 0 05) Conclusion:The results showed that detection of MRD in bone marrow may provide some important information for assessing prognosis,directing treatment and judging curative effect

关 键 词：淋巴瘤 基因重排 微小病灶 NHL 

分 类 号：R733.1[医药卫生—肿瘤]